Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Niagen BioscienceFRA:OCD1 67 Gross Margin % is 63.47% as of Mar. 2026, which is 7% above its 10-year median of 59.47. GuruFocus rates FRA:OCD1 with a GF Score™ of 67/100 and a GF Value™ of €3.98 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 732 Biotechnology companies, Niagen Bioscience ranks better than 54.1% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Niagen Bioscience had a gross margin of 63.47% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Niagen Bioscience Gross Margin % Related Terms
Niagen Bioscience Gross Margin % Historical Data
* Premium members only.
The historical data trend for Niagen Bioscience's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OCD1 vs LCTX, IFRX, VRXA: Gross Margin % Comparison
For the Biotechnology subindustry, Niagen Bioscience's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Niagen Bioscience Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Niagen Bioscience's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Niagen Bioscience's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Niagen Bioscience (FRA:OCD1) has a Gross Margin % of 63.47% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Niagen Bioscience and its competitors. This is near median its historical median of 59.47. Over the past decade, Niagen Bioscience's Gross Margin % has ranged from 47.96 to 64.28. According to the industry distribution chart, Niagen Bioscience ranks #336 out of 732 companies in the Biotechnology industry, placing it in the top 45.9%.
Is Niagen Bioscience's Gross Margin % too high?
Niagen Bioscience's current Gross Margin % of 63.47% is near median its 10-year median of 59.47. Over the past 10 years, this metric has ranged from a low of 47.96 to a high of 64.28. The Biotechnology industry median Gross Margin % is 60.92. Niagen Bioscience's value of 63.47% is 4.2% above this industry median. Based on the distribution chart, Niagen Bioscience ranks #336 out of 732 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Niagen Bioscience has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Niagen Bioscience's Gross Margin % compare to LCTX and IFRX?
According to the Biotechnology industry distribution chart, Niagen Bioscience ranks #336 out of 732 companies for Gross Margin %. This puts Niagen Bioscience in the upper half of its industry. The industry median Gross Margin % is 60.92. Niagen Bioscience's value of 63.47% is 4.2% above this benchmark. Historically, Niagen Bioscience's own Gross Margin % has ranged from 47.96 to 64.28 over the past decade. While the company's 10-year median is 59.47 vs. the industry median of 60.92, Niagen Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Niagen Bioscience's current Gross Margin % of 63.47% is 4.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Niagen Bioscience and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Niagen Bioscience's current Gross Margin % is 63.47%, which is near median its own 10-year median of 59.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niagen Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Niagen Bioscience (FRA:OCD1) is currently considered Possible Value Trap. The stock's GF Value™ is €3.98, compared to a current price of €2.58 — trading 35.2% below its estimated fair value. The current Gross Margin % is 63.47%, which is near median its 10-year median of 59.47 and 4.2% above the Biotechnology industry median of 60.92. Niagen Bioscience's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Niagen Bioscience (FRA:OCD1), the current Gross Margin % is 63.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Niagen Bioscience (FRA:OCD1) Overvalued in 2026?
Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued.
The current stock price of €2.58 is trading 35.2% below its estimated GF Value™ of €3.98.
GuruFocus considers Niagen Bioscience to be Possible Value Trap.
Key valuation signals for FRA:OCD1:
Gross Margin %: 63.47% (near median its 10-year median of 59.47)
GF Value™: €3.98 vs. price of €2.58 (35.2% below fair value)
Industry Position: 4.2% above the Biotechnology median (#336 of 732)
No single metric tells the full story. See the FRA:OCD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
67GF Score
Get the complete analysis for FRA:OCD1
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OCD1 has been successfully added to your 
